Aspartylglucosaminuria (AGU) is a lysosomal storage disexpression of AGA was demonstrated in the liver. The ease leading to mental retardation, which is caused by adenovirus vectors were also injected intraventricularly into deficiency of aspartylglucosaminidase (AGA). AGU is the brain of AGU mice resulting in AGA expression in the strongly enriched in the Finnish population in which one ependymal cells lining the ventricles, and further, diffusion major mutation called AGU Fin has been identified. The molof AGA into the neighbouring neurons. Also, AGA enzyme ecular pathogenesis of AGU as well as the biology of the injected intraventricularly was shown to transfer across the AGA enzyme have been extensively studied, thus giving a ependymal cell layer. One month after administration of the profound basis for therapeutic interventions. In this study wild-type Ad-AGA, a total correction of lysosomal storage we have performed adenovirus-mediated gene transfer to in the liver and a partial correction in brain tissue surroundthe recently produced mouse model of AGU, which exhibits ing the ventricles was observed. After administration of the similar pathophysiology as that in humans. Recombinant Ad-AGU virus the lysosomal storage vacuoles in liver or adenovirus vectors encoding for the human AGA and brain remained unchanged. These data demonstrate that AGU Fin polypeptides were first applied in primary neurons the lysosomal storage in AGU can be biologically corrected of AGU mouse to demonstrate wild-type and mutant AGA and furthermore, in the brain a limited number of expression in vitro. In vivo, both of the adenovirus vectors transduced cells can distribute AGA enzyme to the were injected into the tail vein of AGU mice and the surrounding areas.
Introduction
The deficiency of human aspartylglucosaminidase (AGA) causes a lysosomal storage disease aspartylglucosaminuria (AGU) characterized with accumulation of uncleaved glycoasparagines in lysosomes. 1 The enzyme deficiency results in progressive mental retardation and death between 30 and 40 years of age. In Finland, one major point mutation, AGU Fin is found, 2 whereas foreign mutations are typically different and family specific. The cell biological consequences of different mutations have been characterized [3] [4] [5] and most of them result in formation of truncated polypeptide or inactive enzyme due to defective folding. The intracellular processing and transport of AGA has been studied in detail. 6, 7 AGA is synthesized as a precursor polypeptide which becomes proteolytically activated in the endoplasmic reticulum resulting in ␣ and ␤ subunits. The mature enzyme is an ␣ 2 ␤ 2 heterotetramer, which is also partially secreted and endo-cytosed by recipient cells by mannose-6-phosphate receptor. 8 The three-dimensional structure determination has enabled the characterization of the active site, catalytic mechanism and the lysosomal recognition determinant of AGA. [9] [10] [11] Accordingly, the molecular details of the protein structure and cellular metabolism are exceptionally well analyzed.
The recently generated mouse models of AGU 12, 13 exhibit similar pathophysiology as compared to the human disease: AGA deficiency, secretion of glycoasparagines into urine, vacuolar storage lysosomes in visceral organs and brain and specific brain changes in magnetic imaging. The vacuoles are present already in 19-day-old fetuses. Old AGU mice also have differences of performance in behavioral tests as compared with the wild-type mice. 13 Currently, there is no appropriate treatment for AGU or other lysosomal diseases affecting the central nervous system (CNS). Previously, enzyme deficiency in AGU patient fibroblasts has been corrected with retrovirus-mediated gene transfer in vitro 8 and bone marrow transplantation has been applied to human AGU patients, but due to long follow-up time conclusive results do not yet exist. 14 Other possible treatments include enzyme replacement therapy and gene therapy.
The mouse model of AGU enables different therapy trials and replication-deficient adenoviral vector is an attractive method for gene therapy of AGU, because unlike, for example, retrovirus it enables gene delivery and expression in post-mitotic cells. For enzyme replacement direct injection of enzyme into mouse brain offers the possibility of skipping the blood-brain barrier.
Adenovirus vector has been applied in gene transfer of brain cells including oligodendrocytes, astrocytes, neurons and ependyma. [15] [16] [17] [18] [19] For CNS diseases, adenovirus vectors have previously been successfully used in rat models of Parkinson's disease, 20 Alzheimer's disease, 21 glioma, 22 Lesch-Nyhan syndrome 23 and hypothalamic diabetes insipidus. 24 Here we describe adenovirusmediated AGA expression in primary neurons in vitro and in AGU mouse liver and brain in vivo. AGA was shown to diffuse across the ependymal cells to the brain tissue after intraventricular injection of the virus or purified AGA enzyme. Adenovirus-mediated expression of AGA lasted for at least 4 months and disappearance of lysosomal storage in liver and decrease in vacuoles in neural tissue surrounding the brain ventricles could be demonstrated.
Results

Expression of adenovirus-derived AGA in primary neurons
The replication-deficient recombinant adenoviral vectors Ad-AGA and Ad-AGU were constructed to express the human wild-type AGA cDNA and mutagenized AGU Fin cDNA (G488C + G482A) under transcriptional control of the RSV LTR promoter. The recombinant viruses were first tested in 293 cells and AGU mouse fibroblasts to ascertain that the Ad-AGA virus produced correctly processed active AGA enzyme and that the Ad-AGU virus produced a mutant inactive precursor polypeptide. In AGU mouse fibroblasts the enzymatic activity was raised three-fold over the normal level after infection with Ad-AGA. Telencephalic primary neuron cultures prepared from E14 AGU-mouse 13 embryos were infected with Ad-AGA or Ad-AGU with a multiplicity of infection (MOI) of 5-500. Expression of adenovirus-mediated AGA in neurons was detected by double immunofluorescence labeling with rabbit anti-human AGA and mouse antineurofilament 160 kDa as a neuronal marker. The infected neurons showed AGA immunopositivity 4 days following infection whereas uninfected AGU control neurons did not express detectable amounts of AGA ( Figure  1 ). Neurofilament expression was found to decrease in part of AGA positive cells during the culturing time predicting degeneration of cytoskeleton and cell death. A MOI of 125 plaque forming units (p.f.u.) per cell was found to give an optimal compromise between infection and toxicity. The wild-type AGA enzyme produced by Ad-AGA was detected as a punctate staining pattern seen also in the neurites of primary neurons whereas the mutant AGU polypeptides produced by Ad-AGU remained mainly in the soma (Figure 1 ).
Adenovirus-mediated AGA expression in AGU mouse liver and brain To study adenovirus-mediated expression of AGA enzyme in AGU mouse liver, 1 × 10 9 infectious virions were injected into tail vein under anesthesia. Injections were performed with the two viral constructs Ad-AGA and Ad-AGU. The Ad-AGA-mediated AGA expression was monitored at RNA and protein levels. The adenovirus-derived AGA transcript was detected at several time-points from total liver RNA by RT-PCR using human AGA-specific primers, which did not recognize endogenous AGU mRNA of the knock-out mice. The AGA expression in AGU mouse liver was found to prevail for at least 4 months as detected by RT-PCR ( Figure  2a ). Western blot analysis from concanavalin A-purified samples from liver demonstrated that in vivo the adenovirus-derived AGA polypeptide had been processed into the active subunit form, and the enzymatic activity in liver was 17% of wild-type activity (Figure 2b ). Immunohistochemical staining of AGA from paraffin-embedded tissue sections with AGA antiserum was further used to detect the AGA polypeptide in liver. Starting from 1 week after the injection a portion of hepatocytes was found to express AGA as a punctate staining pattern in the cytoplasmic region ( Figure 2c ). For in vivo expression of AGA in brain, anesthesized mice were injected with 8 × 10 7 p.f.u. of Ad-AGA or Ad-AGU into the left lateral ventricle. In brain injections, the Ad-␤-gal virus 25 was used as a control because unlike AGA ␤-gal is a nuclearly targeted protein and is not expected to migrate outside an infected cell. AGA expression was monitored at several time-points by RT-PCR and immunohistochemical staining. Ependyma of both hemispheres was found to express AGA. Due to the local expression of AGA, exact enzymatic activities were difficult to analyze. In a lysate prepared from a section around the ventricles, marginal enzymatic activity of Ͻ5% of wild-type, could be detected. In the case of Ad-␤-gal only ependymal cells of the ventricles were ␤-gal positive, whereas immunostaining of AGA was also found in neighboring neurons ( Figure 3 ). Mild periventricular microglial activation persisted in Mac-1 immunostaining throughout the whole follow-up time of 1 week to 3 months (Figure 3 ), but no gliosis mediated by the virus infection was detected as determined by astroglial GFAP immunostaining performed for each brain section ( Figure 3 ). RT-PCR from RNA of adenovirus-treated AGU mouse brain was positive for AGA for 4 months, which was the longest time followed in this experiment ( Figure 2a ).
Enzyme substitution with intraventricular injection of recombinant AGA enzyme AGA enzyme was also used for intraventricular injections to study the transfer of the enzyme across the ependymal cell layer lining the ventricles. Purified human AGA enzyme (500 ng), produced by a recombinant CHO-AGA cell line, was injected into the left lateral ventricle of AGU mice. Diffusion of the enzyme was monitored by immunohistochemical staining with AGA antiserum. Immunoreactivity was found mainly in ependyma ( Figure 3 ) of both hemispheres in 1 week and in the neighbouring neurons in 2-4 weeks (not shown). GFAP immunostaining after enzyme injection showed no inflammatory response. monitored using toluidine blue stained 1-m thick epoxy resin sections. Electron microscopy (EM) was used in order to confirm the lysosomal nature of the vacuoles in the liver and periventricular areas of the brain (basal ganglia, thalami). Age-matched AGU mice injected with the Ad-AGU virus producing inactive enzyme were used as controls. Total correction of lysosomal storage in sinusoidal Kupffer cells of the liver was found 1 month after injection of Ad-AGA into the tail vein, whereas the Kupffer cells of control AGU mice injected with the Ad-AGU virus were full of storage lysosomes both in light ( Figure 4 ) and electron microscopy. However, 3 months after the injections, lysosomal storage vacuoles started to reappear. In the brain, 1 month after Ad-AGA injection, the lysosomal vacuoles had decreased in neurons around the ventricles, whereas plenty of vacuoles were present in a control AGU mouse. A pronounced effect was found in perithelial cells surrounding the vessels 2 months after injection ( Figure 5 ). The quantitative difference in the amount of vacuoles between treated and untreated or Ad-AGU-treated control mice prevailed even after 6 months, which was the latest time followed after the intraventricular injections.
Discussion
Replication-deficient adenovirus vector is a promising gene transfer vehicle for diseases affecting brain due to its ability to infect a wide variety of cells and particularly nondividing cells. The only limitation is transient expression and immunogenicity after repeated use. In CNS diseases, the optimal target for gene therapy would be a single gene defect affecting a specific, limited group of cells. The AGU disease is an example of monogenic recessive disease affecting all tissues. In AGU the most severe symptoms, which are also the most challenging to cure, originate in the CNS. The recently generated knockout mouse model for AGU exhibits a similar pathophysiology to humans 13 and is therefore an ideal model to study in vivo gene therapy of brain cells.
To test AGA gene transfer into the AGU mouse, we generated wild-type Ad-AGA and mutant Ad-AGU replication-deficient adenoviruses. The viruses were first tested in vitro in primary neurons obtained from AGU mouse embryos, which showed the expected functional difference between the expression product of the wildtype Ad-AGA and the mutant Ad-AGU. The wild-type AGA polypeptides were transported to neural extensions whereas the AGU polypeptides produced by the Ad-AGU virus remained mainly in the soma and demonstrated no enzymatic activity.
Previous in vitro studies have shown that the wild-type AGA enzyme is produced after dimerization and proteolytic processing of the gene product in the ER, from where the active enzyme is transported to lysosomes. The AGU Fin polypeptide is incorrectly folded, does not dimerize and remains as a nonphosphorylated inactive precursor polypeptide which is not transported to lysosomes. 5, 7, 26 We have also recently shown that the secreted wild-type AGA is endocytosed by mouse primary neurons via the mannose-6-phosphate receptor pathway (Kyttälä et al, unpublished) . Consequently, here we have an interesting model system to analyze whether the adenovirus-mediated AGA would migrate in the brain tissue after intraventricular injection.
In vivo, we used the Ad-AGA and Ad-AGU adenoviral vectors to transfer AGA cDNA to the ependymal cells lining the ventricles. These cells have many characteristics of epithelial cells and thus are ideal targets for adenoviral infection. It has been shown previously that injection of recombinant adenovirus into the lateral ventricle leads to infection of the ependymal cells also on the contralateral side and in the third and fourth ventricle. The choroid plexus is not infected. 16 The injections of recombinant viruses in vivo into the AGU mouse brain showed no inflammation peak or gliosis related to the viral injection, but mild periventricular microglial activation persisted throughout the whole follow-up time. The AGA immunostaining prevailed in the ependymal cells lining the ventricles and expressed AGA was also found in the surrounding brain areas. Other reports of adenovirus-mediated gene expression in the brain have indicated inflammation during the first 2 weeks after injection 27 which has been shown to be mainly infiltration of macrophages and T cells. In general, the immune system plays an important role in the decline of gene expression directed by adenoviral vector. However, adenovirus-mediated gene therapy has been reported to lead to a longer expression in brain than in other organs. 15, 17 We previously found that even in the normal brain the AGA expression is relatively low, and therefore, the most important goal of therapy would be to establish a long lasting but not necessarily a high level of AGA expression in the AGU mouse brain. In this case, the adenovirusmediated AGA expression in AGU mouse brain continued for at least 4 months (latest time-point analyzed), which is in accordance with earlier reports of first-generation adenovirus vectors. Adenovirus-mediated or directly injected AGA enzyme also diffused across the ependymal cell layer lining the ventricles and resulted in a partial correction of the lysosomal storage in brain tissue close by. This is important because not all cells in the brain tissue need to be infected by a gene transfer virus. Previously, the effect of gene therapy to lysosomal storage in the brain has been monitored only in mucopolysaccharidosis (MPS) type VII mouse, where local correction of storage was described in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting ␤-glucuronidase -and total correction in brain after neural progenitor cell engraftment to newborn mouse lateral ventricle. 28, 29 Adenovirus vector offered the possibility of infecting cells of CNS origin directly without laborious cell grafts.
In the liver, after tail vein injection of viral particles, a total correction of lysosomal accumulation was shown after 1 month. After that, adenovirus-mediated AGA expression continued for at least 4 months, but probably at the minimal level since lysosomal accumulation started to appear after 3 months. It is possible that in the liver a much higher level of AGA expression is needed to restore the normal cellular function than in the brain. The most important target organ for gene therapy in AGU is the CNS, where we could demonstrate that the adenovirusmediated AGA caused a partial correction of a lysosomal accumulation. Importantly, here we used adenovirus producing a mutant inactive AGA enzyme as a control to ensure that any demonstrated tissue change truly resulted from the active AGA enzyme and not from any virus-mediated function.
These therapy trials were performed using young AGU mice aged from 1 to 2 months. Since the total correction of brain tissue was not obtained, it cannot be estimated, at this time, whether the actual brain damage in AGU is reversible, or at which age the therapeutic efforts should be applied. This question remains to be answered, and despite the encouraging initial local correction of lysosomal storage in brain, improved vectors without immunogenicity even after repeated injections will be needed to ensure a long-lasting expression resulting in total correction of the lysosomal storage in the cortical and thalamic brain areas.
Materials and methods
Adenoviral constructs
The recombinant E1/E3-deleted adenoviruses were prepared by first inserting the wild-type human AGA cDNA and the mutated AGU Fin cDNA (contains a double point mutation G488C + G482A 2 ) into pAdPsy-LTRSVpolyA vector. The pAdPsy-LTRSVpolyA vector contains the adenoviral sequences needed for subsequent homologous recombination. Transcription of AGA is controlled by the Rous sarcoma virus (RSV) LTR promoter. The linearized DNA vectors were cotransfected into 293 cells together with the large fragment of ClaI-digested DNA of Ad5 (E3 deleted). The recombinant AGA and AGU Fin adenoviruses produced by homologous recombination were collected as described previously. 25 The viruses were plaque purified three times and the final virus stocks were purified by two rounds of CsCl density gradient centrifugation and separated in a Sephadex PPD column (Pharmacia Biotech, Uppsala, Sweden) in PBS. Viral titers were determined by infection of 293 cells with serial dilutions and the viral preparations were tested for the presence of replication-competent wild-type virus by PCR.
Mouse strains
Homozygous AGU knock-out mice 13 inbred against C57/bl mouse strain were used in the virus injections. Wild-type C57/bl mice were used as a normal control in analyses. All the animal experiments were approved in commission of laboratory animals.
Primary neuron cultures
Telencephalic cultures were obtained from E14 AGU mouse embryo brain. Meningeal membranes were removed in ice-cold 20 mm glucose in phosphate-buffered saline (PBS) and the tissue was pulled into small pieces, trypsinized for 15 min, centrifuged and pipetted to produce a single-cell suspension. The cells were plated to poly-d-lysine hydrobromide coated coverslips at a density of about 8 × 10 2 cells/mm 2 in DMEM containing 1 × B27 (Gibco BRL, Grand Island, NY, USA), 1% heatinactivated fetal bovine serum, penicillin/streptomycin, 0.5 mm glutamine and 25 m glutamate. The cells were maintained at 37°C under 5% CO 2 . After 3-4 days the medium was replaced containing no exitatory glutamate but 5 m Ara-C (Sigma, St Louis, MO, USA) was added to prevent proliferation of glial cells.
Adenoviral infections of neurons
Primary neuron cultures were infected with Ad-AGA or Ad-AGU 1-2 days following plating in FCS-free DMEM for 2 h. The cells were infected with a MOI of 5-500 and preinfection media were reused after infection. To follow the expression of adenovirus-mediated wild-type or mutant AGA, immunoreactivity was tested 3-6 days following the infection.
Immunofluorescence
For immunofluorescence staining primary neurons were fixed with 4% paraformaldehyde in PBS at room temperature for 15 min. The cells were washed twice with PBS, permeabilized with 0.1% Triton X-100 and nonspecific staining was blocked with 0.5% BSA in PBS. Double staining was performed using a rabbit anti-human AGA 30 at a 1:400 dilution and a mouse anti-neurofilament 160 kDa (Boehringer Mannheim, Germany) at a 1:16 dilution as primary antibodies. Corresponding secondary antibodies were goat anti-rabbit rhodamine and goat antimouse fluorescein (1:150, Immunotech, Marseille, France). The staining was analyzed using the Leica confocal microscope.
Animal injections
For tail vein injections mice were anesthetized with Hypnorm (Janssen-Cilag, Saunderton, UK). 1 × 10 9 infectious virions (either Ad-AGA, Ad-AGU or Ad-␤-gal) at a 1:2 dilution in 0.9% saline in a volume of 100 l was injected using a 28-gauge needle. For intraventricular injections mice were anesthesized with Dormicum (Hoffman-La Roche, Basel, Switzerland)/Hypnorm mixture. Four microliters of a viral stock solution (either Ad-AGA, Ad-AGU or Ad-␤-gal) at 2 × 10 10 p.f.u./ml, 0.3 l/min or 4 l of 125 ng/l 0.5 l/min purified human AGA enzyme produced by CHO-AGA cells was stereotactically administered with a Hamilton microsyringe to the left lateral ventricle (laterality 1 mm from bregma, depth 3 mm). Age-matched control AGU mice were injected similarly with the same volume of 0.9% saline. Temgesic was used as a post-operative painkiller. Mice were killed at various times (1 week-6 months) following injections using Mebunat (pentobarbitone sodium, 80-150 mg/kg; OrionFarmos, Turku, Finland) and were then intracardially perfused using 40 ml of 0.9% saline followed by 40 ml of 4% paraformaldehyde (PFA) in PBS. The brains or livers were removed and post-fixed in the same fixative for 3 h at room temperature. For intraventricular injections of human AGA, enzyme produced and secreted by a recombinant CHO-AGA cell line was purified and concentrated as described previously. 8 For analyses of RNA and Western blot mice were not perfused but the organs were frozen.
The AGU mice used for adenovirus injections were treated in the following groups/number. For tail vein injections 12 mice were injected with Ad-AGA and 12 AGU mice with Ad-AGU. The mice were killed at 7 days, 1 month, 2 months, 3 months and 4 months, two mice per virus per time-point. For intraventricular injections, 14 AGU mice were injected with Ad-AGA and seven with Ad-AGU. Sampling was at 7 days, 14 days, 1 month, 2 months, 3 months, 4 months and 6 months. Two Ad-AGA mice and one Ad-AGU mouse were killed per timepoint. Additionally, three mice were injected with Ad-␤-gal and sampled at 7 days and 14 days. For each sample NaCl-treated mice were killed to serve as a nonvirus control for histology. Six mice were intraventricularly injected with AGA enzyme and prepared.
Analysis of RNA RNA was isolated from 30 mg of frozen mouse brain or liver samples with Rnaeasy Minikit (Qiagen, Hilden, Germany) and cDNA was synthesized by reverse transcription from 2 g of total RNA using human-specific AGA primer. The cDNA was used for PCR amplification with human AGA primers. The PCR products were visualized in 1% agarose gel.
Western blot analysis
Liver homogenates were prepared from frozen samples. The proteins were ammonium sulfate precipitated and concanavalin A (Pharmacia Biotech) purified. The glycoprotein fractions were separated by 14% SDS-polyacrylamide gel electrophoresis, 31 electroblotted on to nylon membranes and immunostained using a rabbit antimouse GST/AGA antiserum, which crossreacts with human AGA. 32 The blots were incubated with anti-rabbit alkaline-phosphatase conjugate (Promega, Madison, WI, USA) and visualized by NBT-BCIP substrate (Promega).
Immunohistochemistry and histology PFA-perfused and -postfixed brains and liver pieces from inferior part of great liver lobe were either embedded in paraffin, cut into 8 m/5 m sections, mounted on to APE (Sigma)-coated glass slides and stained immunohistochemically, or osmicated, embedded in epoxy resin, cut into 1 m sections and stained with toluidine blue. For immunohistochemical staining paraffin-embedded coronal brain and liver sections were rehydrated and stained with a rabbit antiserum to human AGA at a dilution of 1:200. Brain sections were also stained using rabbit anti-GFAP (1:200, Dako, Denmark), monoclonal ␤-gal (1:2000, Boehringer) and rat anti-mouse Mac-1 (CD11b, 1:100, Serotec, Oxford, UK). Endogenous peroxidase activity was blocked with 5% H 2 O 2 . Biotinylated secondary antibodies (goat anti-rabbit IgG, horse anti-mouse IgG, rabbit antirat IgG; Vector, Burlingame, CA, USA) were used at a dilution of 1:200. Visualization was achieved using biotin/avidin-peroxidase (Vector), 0.03% H 2 O 2 and 0.15% nickel-reinforced 0.05% diaminobenzidine (DAB) as a chromogen.
Assay for AGA activity Treated AGU mouse liver homogenates and brain samples from the periventricular region were prepared from frozen samples. Before the assay, the proteins were concentrated by ammonium sulphate precipitation and concanavalin A purification. The AGA activity assay is based on the colorimetric measurement of liberated Nacetylglucosamine from the synthetic substrate AADG (Sigma) 33 and the assay was performed as described earlier. 5 Puhakka and Maire Nurmi are acknowledged. The research project was supported by the Maud Kuistila foundation, the Academy of Finland, the Juselius Foundation and the Hjelt Fond.
